A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Active, not recruiting · Phase 3 · NCT02993523
Conditions: Acute Myeloid Leukemia (AML)
At a glance
- Research payments reported, 2025
- $6,203
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 443
About the trial
- Sponsor
- AbbVie (with Genentech, Inc.)
- Tested
- Azacitidine (drug), Venetoclax (drug), Placebo (drug)
- Dates
- Started 2017-02-02; completion 2026-06-15
- Results posted
- Yes
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own. This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are \>= 18 or more years old and ha…
From ClinicalTrials.gov, last updated 2026-06-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $6,203 in research payments for this study in 2025 (2 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fort Wayne Medical Oncology & Hemat $6,203
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.